WOBURN, Mass., July 15 /PRNewswire/ -- BioTrove, Inc. announced today that
the Company has acquired an exclusive license from Stanford University for
patent applications that cover the use of a through-hole structured microarray
to perform PCR. Separately, BioTrove has been issued a patent on a novel
method using the Company's proprietary OpenArray(TM) platform for high-density
cell assay and culture. BioTrove is commercializing its OpenArray(TM)
platform, a nanofluidic system for massively parallel analysis using Thru-
Hole(TM) technology, for use by life science researchers.
"The Stanford patent applications and the cell maintenance patent are
important parts of our large and growing patent portfolio around BioTrove's
Thru-Hole(TM) technology," remarked Robert Hess, Director of Licensing and
Intellectual Property at BioTrove. "We identified these patent applications
as potentially valuable because the inventors, Matthew O'Keefe and Pamela
Foreman, were early to see the utility of performing high-density, parallel
gene amplification in a through-hole structure." The new BioTrove patent
covers an innovative application of BioTrove's OpenArray(TM) technology that
allows for the maintenance and growth of cells in a microfluidic environment,
with potential application in cell-based assays.
Both the licensing and the new patent strengthen BioTrove's existing
through-hole array patent portfolio. BioTrove's through-hole intellectual
property portfolio includes eight patents issued or allowed and numerous
The OpenArray(TM) platform includes a nanotiter plate requiring only
nanoliter-sized quantities of sample per through-hole. It can be used for
massively parallel and low-volume analysis of genetic, genomic, proteomic,
biochemical and cellular samples. The platform uniquely combines the
parallelism of microarrays with the data quality of PCR to perform genetic and
genomic assays, including genotyping and RNA expression analysis.
About BioTrove, Inc.
BioTrove, Inc. is a biotechnology company focused on advancing life
science and drug discovery research by leveraging revolutionary micro- and
nano-scale technologies. BioTrove has two core platforms: OpenArray(TM)
Applications based on Thru-Hole(TM) technology, a broadly applicable nano-
liter fluidics technology platform for massively parallel and low-volume
analysis of genetic, genomic, proteomic, biochemical and cellular samples, and
RapidFire(TM) Lead Discovery, an assay development and high throughput
screening service that unlocks the value of intractable drug targets. For
more information on BioTrove, please visit the company's website at
For information contact:
Patrick T. Carroll
Feinstein Kean Healthcare
SOURCE BioTrove, Inc.